Kurs
-2,36%
Kurs
-2,36%
Open
63,50
High
63,50
Low
60,50
Close
62,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Est. tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | N/A | X-dag ordinarie utdelning GENT 0.40 NOK |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | N/A | Årsstämma |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-29 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2021-05-04 | - | Årsstämma |
| 2021-04-16 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-07-13 | - | Extra Bolagsstämma 2018 |
| 2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-06-06 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-02-18 12:02:41
Moss, 18 February 2021
Gentian Diagnostics AS today announces that its patent application for a highly
sensitive particle enhanced assay for the quantification of NT-proBNP has been
published by the World Intellectual Property Organization (PCT Application No.
PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in
this patent application enables Gentian to develop and commercialize an
automated and fast NT-proBNP assay for open turbidimetric clinical chemistry
platforms.
The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of
congestive heart failure (CHF), is planned for 4Q 2021. The assay under
development by Gentian Diagnostics will enable improvement of laboratory
productivity based on higher throughput in comparison to currently used assays
and contribute to the harmonization and standardization of the NT-proBNP assays.
Going forward, the Company will announce when patents are granted.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525